Interview >> Dr. Michael Quirmbach >> A Decade of CordenPharma

Jul 25, 2016
Pharmaceutical Technology Interviews Dr. Michael Quirmbach, Vice President, Global Marketing & Sales, CordenPharma International >

A Decade of CordenPharma > From Inception to Full‑Service Provider

CordenPharma differentiates itself through its technology platforms.


Visiongain estimates that the global contract pharmaceutical manufacturing market will grow from $54.54 billion in 2013 to $79.24 billion in 2019, making competition in this space fiercer than ever. Pharmaceutical Technology recently spoke with Dr. Michael Quirmbach, Vice President, Global Marketing & Sales, CordenPharma International, about the strategies his company has put in place, both short- and long-term, to differentiate itself in the market.

Pharmaceutical Technology: What strategy or business model have you developed over the past decade to grow so rapidly into a full-service provider?

Michael Quirmbach: Our strategy has been to acquire assets from Big Pharma companies that are no longer key to them. We took those facilities and turned them around to form a Contract Development & Manufacturing Organization (CDMO). These facilities have become our core value proposition because we recognize the opportunity their expertise, infrastructure and experience bring to our network. We will continue with this model. We have benefited from acquiring high quality assets and employees around which we will continue to expand our full-service service offerings.

Pharmaceutical Technology: How does CordenPharma differentiate itself from competitors in terms of full-service offerings?

Michael Quirmbach: Our full-service offerings span broadly across Active Pharmaceutical Ingredient (API) and Drug Product manufacturing from R&D to commercial scale in areas such as antibiotics, peptides, small molecules, injectables and highly potent oncology products. This multi-layered matrix of capabilities is a major differentiation of our offerings compared to the competition.

Pharmaceutical Technology: Could you describe CordenPharma’s market approach as it relates to your technology platforms?

Michael Quirmbach: In the last two-and-a-half years, we have created a market strategy based on our customers’ needs. Our goal is to concisely communicate about our capabilities through what we call technology platforms, and to demonstrate how these platforms benefit customers.

We currently have five technology platforms: Highly Potent & Oncology; Small Molecules; Injectables; Peptides, Lipids, & Carbohydrates; and finally, Antibiotics. These capabilities are present across multiple facilities, which provide an integrated network of development and commercial support.

Furthermore, CordenPharma has addressed the important concept of one-stop shopping by having single points of contacts for customers. We have dedicated Key Account Managers who represent all the technology platforms, and Platform Directors who are responsible for the go-to-market strategy, including customer and project targeting and proposing new investments in facilities and technology.

Read the Full Interview Here.

Listen to a Podcast Version Here.